survival (version 3.5-8)

colon: Chemotherapy for Stage B/C colon cancer

Description

These are data from one of the first successful trials of adjuvant chemotherapy for colon cancer. Levamisole is a low-toxicity compound previously used to treat worm infestations in animals; 5-FU is a moderately toxic (as these things go) chemotherapy agent. There are two records per person, one for recurrence and one for death

Usage

colon
       data(cancer, package="survival")

Arguments

Format

id:id
study:1 for all patients
rx:Treatment - Obs(ervation), Lev(amisole), Lev(amisole)+5-FU
sex:1=male
age:in years
obstruct:obstruction of colon by tumour
perfor:perforation of colon
adhere:adherence to nearby organs
nodes:number of lymph nodes with detectable cancer
time:days until event or censoring
status:censoring status
differ:differentiation of tumour (1=well, 2=moderate, 3=poor)
extent:Extent of local spread (1=submucosa, 2=muscle, 3=serosa, 4=contiguous structures)
surg:time from surgery to registration (0=short, 1=long)
node4:more than 4 positive lymph nodes
etype:event type: 1=recurrence,2=death

References

JA Laurie, CG Moertel, TR Fleming, HS Wieand, JE Leigh, J Rubin, GW McCormack, JB Gerstner, JE Krook and J Malliard. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil: The North Central Cancer Treatment Group and the Mayo Clinic. J Clinical Oncology, 7:1447-1456, 1989.

DY Lin. Cox regression analysis of multivariate failure time data: the marginal approach. Statistics in Medicine, 13:2233-2247, 1994.

CG Moertel, TR Fleming, JS MacDonald, DG Haller, JA Laurie, PJ Goodman, JS Ungerleider, WA Emerson, DC Tormey, JH Glick, MH Veeder and JA Maillard. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New England J of Medicine, 332:352-358, 1990.

CG Moertel, TR Fleming, JS MacDonald, DG Haller, JA Laurie, CM Tangen, JS Ungerleider, WA Emerson, DC Tormey, JH Glick, MH Veeder and JA Maillard, Fluorouracil plus Levamisole as an effective adjuvant therapy after resection of stage II colon carcinoma: a final report. Annals of Internal Med, 122:321-326, 1991.